VBI Vaccines (NASDAQ:VBIV) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of VBI Vaccines (NASDAQ:VBIVFree Report) in a research note released on Tuesday. The firm issued a sell rating on the biopharmaceutical company’s stock.

VBI Vaccines Stock Performance

Shares of VBI Vaccines stock opened at $0.70 on Tuesday. The stock has a market capitalization of $16.58 million, a P/E ratio of -0.06 and a beta of 1.93. VBI Vaccines has a 52-week low of $0.45 and a 52-week high of $9.54. The stock’s 50-day simple moving average is $0.61 and its 200 day simple moving average is $0.62.

Institutional Trading of VBI Vaccines

A number of hedge funds have recently bought and sold shares of VBIV. Engineers Gate Manager LP purchased a new stake in shares of VBI Vaccines in the first quarter worth $26,000. Point72 Hong Kong Ltd bought a new position in VBI Vaccines in the second quarter valued at about $29,000. Barclays PLC lifted its holdings in VBI Vaccines by 89.9% in the first quarter. Barclays PLC now owns 98,337 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 46,566 shares during the period. Voya Investment Management LLC lifted its holdings in VBI Vaccines by 29.7% in the fourth quarter. Voya Investment Management LLC now owns 95,428 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 21,824 shares during the period. Finally, BNP Paribas Arbitrage SA raised its stake in shares of VBI Vaccines by 208.7% in the second quarter. BNP Paribas Arbitrage SA now owns 47,668 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 32,227 shares during the period. Institutional investors own 12.26% of the company’s stock.

VBI Vaccines Company Profile

(Get Free Report)

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.

Recommended Stories

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.